NCT07250477RecruitingPhase 2
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
Source: ClinicalTrials.gov · Last updated 25 Aug 2026
Brief summary (registry, in English)
This is a phase 2, pragmatic, 1:1 randomized, open-label study that evaluates risk-adapted, proteomic-guided systemic therapy to improve 12-month progression free survival (PFS) among patients with previously untreated advanced non-small cell lung cancer.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 56 (estimated)
- First submitted
- 18 Nov 2025
- Start date
- 30 Jan 2026
- Primary completion date
- 31 May 2036
- Lead sponsor
- University of California, Davis
- Diseases
- Lung cancer
- NCT number
- NCT07250477
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 56
- From 30 Jan 2026 to the primary completion date, 31 May 2036
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Medical comorbidities precluding immune checkpoint inhibitor-based therapy per treating investgator's discretion.
- Previous systemic therapy for metastatic Stage IIIC or IV NSCLC. Patients who previously completed systemic therapy for early stage or locally advanced NSCLC ≥ 80 days prior to trial registration are eligible for inclusion.
Other illness
- Any condition that in the opinion of the investigator would interfere with the participant's safety or compliance while on study
Lab values
- Tumor with known sensitizing alteration in ALK, EGFR, HER2, MET exon 14, NTRK, RET, or ROS1.
Who the study is looking for
- Participants must have histologically confirmed non-small cell lung cancer that is metastatic or unresectable (stage IIIC or IV), deemed appropriate to receive standard of care immune checkpoint inhibitor-based therapy given with palliative intent.
- Age ≥18 years at the time of consent.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥50%).
- Ability to understand and willingness to sign the informed consent form (ICF).
- Stated ability and willingness to adhere to all protocol requirements while on study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Enloe Health Regional Cancer Center Coordinator of this site? Confirm its status | Chico | United States | Recruiting |
| Rideout Cancer Center Coordinator of this site? Confirm its status | Marysville | United States | Recruiting |
| University of California Davis Comprehensive Cancer Center Coordinator of this site? Confirm its status | Sacramento | United States | Recruiting |
| Tahoe Forest Cancer Center Coordinator of this site? Confirm its status | Truckee | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.